On average about 600 people died from COVID each day, down from a peak of over 3,000 deaths per day for most of January. About 37% of the country's population has been fully vaccinated as of Sunday, and 47% has received at least one dose of a COVID-19 vaccine, according to the U.S. Centers for Disease Control and Prevention. In the past seven days, an average of 2 million vaccine doses were administered per day, which is down 2% from the previous week after falling 17% in the prior week.
As more states lift mask rules and other restrictions put in place during the pandemic and businesses start to invite employees back to work in person, the federal government also is working on how to make sure employers are protecting workers from COVID-19. The federal agency charged with protecting workers, the Occupational Safety and Health Administration, has fielded thousands of COVID-19 related complaints since the start of the pandemic and is expected to release an emergency rule to help enforce the steps employers are required to take to keep people safe. OSHA issued almost $4 million in citations for COVID-related complaints, as of the latest update in January and not including citations from state worker safety agencies.
People with immune disorders were excluded from COVID-19 vaccine clinical trials. It's unclear if vaccines are effective for people in this group.
Whenever Joe Glickman heads out for groceries, he places an N95 mask over his face and tugs a cloth mask on top of it. He then pulls on a pair of goggles. He has used this safety protocol for the past 14 months. It did not change after he contracted the coronavirus in November. It did not budge when, earlier this month, he became fully vaccinated. And even though President Joe Biden said on Thursday that fully vaccinated people do not have to wear a mask, Glickman said he planned to stay the course. In fact, he said, he plans to do his grocery run double-masked and goggled for at least the next five years. Sign up for The Morning newsletter from the New York Times Even as a combination of evolving public health recommendations and pandemic fatigue lead more Americans to toss the masks they have worn for more than a year, Glickman is among those who say they plan to keep their faces covered in public indefinitely. For people like Glickman, a combination of anxiety, murky information about new virus variants and the emergence of an obdurate and sizable faction of vaccine holdouts means mask-free life is on hold — possibly forever. “I have no problem being one of the only people,” said Glickman, a professional photographer and musician from Albany, New York. “But I don’t think I’m going to be the only one.” Whether made of bedazzled cloth or polypropylene, masks have emerged as a dystopian political flashpoint during the pandemic. A map of states that enforced mask mandates corresponds closely with how people in those states voted for president. Last year, protesters staged rallies against official requirements to wear masks, built pyres to burn them in protest and touched off wild screaming matches when confronted about not wearing them inside supermarkets. But as more Americans become vaccinated and virus restrictions loosen, masks are at the center of a second round in the country’s culture brawl. This time, people who choose to continue to cover their faces have become targets of public ire. In interviews, vaccinated people who continue to wear masks said they are increasingly under pressure, especially in recent days; friends and family have urged them to relax, or even have suggested that they are paranoid. On a recent trip to the grocery store, Glickman said he was stared down by a man who entered, unmasked. “I’m confused,” the retired news anchor Dan Rather wrote on Twitter last week as backlash mounted on the platform to those still masked. “Why should people care if someone wants to wear a mask outside?” Following the latest guidance from the Centers for Disease Control and Prevention, at least 20 states repealed mask mandates or issued orders that gave vaccinated people exemptions from wearing masks. Other states, including New York, said they were reviewing their rules. But for some people, no newfound freedom will persuade them to reveal their faces just yet. After a year, they say they have grown accustomed to the masks and glad for the extra safety they provide. A day after the CDC’s announcement, George Jones, 82, a retired mail carrier, stood in the sunshine outside of the General Grant Houses where he lives in Harlem in New York City and said his blue surgical mask — though uncomfortable and inconvenient — would stay put for at least another year. “I’m in no hurry; why should I be in a hurry?” said Jones, who became fully vaccinated about a month and a half ago. Until New York City reaches a higher level of vaccination — just 40% are completely vaccinated — he believes it is too risky to unmask. “Being around is more important. That’s what counts. I’m an old man — I’d like to be around as long as I can.” On Broadway, a group of young men walked past him, with not a mask in sight. Jones said he understood: “Young people, they figure they’re invulnerable — and I hope they are.” Public health data shows that masking and social distancing have most likely had far-reaching positive impacts, beyond slowing the spread of COVID-19. While over 34,000 adults died from influenza in the 2018-19 season, this year deaths are on track to remain in the hundreds, according to CDC data. Leni Cohen, 51, a retired kindergarten teacher from New York City who has a compromised immune system, said she planned to continue wearing a mask when she helped out as a substitute teacher. But what she would like more is for her students to stay masked. “Kindergartners, while adorable, are quick to share their secretions,” Cohen wrote in an email listing the illnesses, including colds, strep throat, pneumonia, influenza and parvovirus, that she has caught from her students over the years. “This year is so different!” she continued. “The kids are not sucking on their hair or putting classroom objects or thumbs in their mouths. Their mouths and noses are covered, so I’m (mostly) protected from their sneezes and coughs. I can see keeping up with masks. It is the safest I’ve ever felt in a classroom full of 5- and 6-year-olds.” Barry J. Neely, 41, a composer from Los Angeles, fell ill with the coronavirus in March 2020 and battled symptoms for months. He has also struggled with guilt over whether he had inadvertently infected people he came in contact with before his diagnosis — which came at a time when the government discouraged mask use. He now plans to wear a mask whenever he feels under the weather, in perpetuity. “It’s not hard to wear a mask,” Neely said. “It’s not hard in the least.” He is taking his cue from several East Asian countries, he added, where wearing a mask when you are feeling sick is not just socially acceptable but seen as considerate. “If I possibly spread a virus a year ago, and then learned that wearing a mask is important to prevent spreading this virus, then what’s the harm in wearing it if I have the common cold?” he said. For a number of so-called perma-maskers, the decision is informed by trauma: They endured the coronavirus or witnessed loved ones die, and they say taking off their mask makes them feel terrifyingly vulnerable. After contracting the coronavirus, Glickman fell ill with pneumonia. He still experiences gastrointestinal problems and neurological symptoms, including extreme lightheadedness and problems with his sight. “Floaters” swim in his field of vision, and on one occasion, he said, everything turned yellow. Post-coronavirus trauma appears to be common: A survey of nearly 400 COVID patients by doctors at Agostino Gemelli hospital in Italy showed 30% developed post-traumatic stress disorder after a severe illness. “There is an element of precaution that is brought on by the emotional and psychological impact with what I went through,” Glickman said of his masking. “I don’t think it is necessarily unjustified. I think it is somewhere in the middle.” Cohen also said she recognized possible downsides: “At first, I thought, ‘This is great, I’m never going to get sick again!’” she said, of her plan to wear a mask to teach kindergarten going forward. “Then I realized when I’m trying to teach vowels they can’t see my mouth.” A few say they have been surprised to find that they have grown to enjoy being hidden behind a mask, expressionless and anonymous. “As a woman, we feel like we have to, when we go out in public, put on a little bit of makeup, eyeliner, blush,” said Keela Samis, 57, an attorney from St. Petersburg, Florida, who is vaccinated and does not plan to stop wearing a mask. “With a mask I don’t have to. It simplified my life.” Samis added: “Even if I’m the only person on planet Earth that continues to wear the mask, if that’s what makes me feel comfortable, I’ll wear the mask.” This article originally appeared in The New York Times. © 2021 The New York Times Company
As demand for the coronavirus vaccine wanes, public health officials are shifting from not wasting a single dose to not wasting a single arm - even if it means cracking a multi-dose vial to vaccinate one patient. The Centers for Disease Control and Prevention on Tuesday advised providers not to miss an opportunity to vaccinate someone who wants the shot - even if that means opening a vial containing many doses without knowing if all of them will be used.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. The message prompted public health officials in many states, including Virginia and Maryland, and in the District of Columbia to align with the new guidance and encourage primary-care doctors - who might only vaccinate a few patients at a time - to administer the doses without worrying as much about wastage. The new approach means providers face a painful choice: puncture a vial containing multiple doses, allowing as many as 10 doses to go to waste, or let a patient walk away unvaccinated. "It's going to be a big shift," said Danny Avula, Virginia's vaccine coordinator. "I think a lot of providers are going to struggle with that given four months of completely the opposite message. But we'll continue to reassure them every day." The CDC statement Tuesday says more vaccine may be wasted, making doctors uneasy and raising ethical questions as other nations face vaccine shortages. "It's why we need to strike the right balance," Avula said. "We do need to be good global stewards. We do need to think about people across the world." Early in the vaccine distribution effort, hospitals and other providers were criticized for failing to quickly administer all their doses, leaving some sitting on shelves, despite overwhelming demand from the public. People stalked pharmacies waiting for leftovers. Democratic Gov. Ralph Northam of Virginia required providers to use their vaccine within a week of receiving it. Republican Gov. Larry Hogan of Maryland threatened to withhold vaccine from those who sat on doses. As supplies increased and eligibility expanded, governments and providers held mass vaccination clinics and accepted walk-ups, boosting the rate of fully vaccinated people to about 40 percent in the greater Washington region. About two weeks ago, supply outstripped demand, forcing public health officials to rely on doctor's offices, mobile units and other small sites to vaccinate people who did not want to go out of their way for the shot, are hard to reach or hesitant. Virginia officials last week made policy changes intended to give doctors more flexibility. Under the heading "No Missed Opportunities," they lifted constraints on when providers had to use supplies, said people could get second doses wherever convenient for them and began to explore ways to distribute small shipments - as little as one vial - around the state. David Goodfriend, director of the Loudoun County Department of Health, said the original guidance was to have a plan in place to waste zero doses.That has changed. "We still want them to strive to not miss any doses," he said, "but if it results in wastage to go ahead and vaccinate someone when they wouldn't otherwise get it, open the vial." Once punctured, multi-dose Moderna vials must be used within 12 hours, Pfizer-BioNTech six hours and Johnson & Johnson two hours, and some have cold storage needs, according to the CDC. Amy Popovich, nurse manager at Henrico and Richmond City health districts, said previously nurses were running vials to different hospital floors before the clock ran out. "All of us have treated the vaccine like gold over the past few months," she said. But Jeff Feit, the community and population health manager at Valley Health, a health-care system based in Winchester, said doctors will still be reluctant to give shots at regular visits, adding the fear of wasting doses on top of logistical challenges. "I think we need to be cognizant of operational changes we're asking people to make in the midst of a challenging time with covid," he said. Small and solo practitioners have already overhauled procedures multiple times in the past 14 months, and to offer the vaccine they must follow strict storage requirements, gather and report data, seek consent for minors, and make time to give the injection and observe patients for up to 30 minutes. "It's going to feel bad if we're wasting a vial or two every day at a site," Feit said. "There's a natural instinct to manage the resource." Physicians have advocated for single-dose vials or syringes to reduce the likelihood of waste. Anne Zink, chief medical officer at the Alaska Department of Health & Social Services, said she encountered this dilemma in Hyder, on the U.S.-Canada border, where there were two residents left to vaccinate. "I had to make the decision, do I open one vial and potentially waste four? Or leave two people stranded there an hour and a half by float plane away and not get them vaccinated?" she told reporters last week on a call organized by the Association of State and Territorial Health Officials. Across the nation and locally, wastage rates up until this point have been low - less than one half of one percent compared to an expected wastage rate of 5 percent for other multi-dose vaccines. In Maryland, 6,435 doses have been wasted and more than 5 million shots were administered as of May 6, said Charlie Gischlar, a spokesman for the state health department. A large chunk of those - 1,580 - were lost when a hospital freezer on the Eastern Shore broke; in other cases there were defective syringes, broken vials and vaccines thawed and not used, he said. In Virginia, 5,168 doses were wasted and about 6 million shots were administered as of May 3, according to state health department data. In D.C., 1,587 doses were wasted and 558,319 doses administered as of May 13, a D.C. Health spokeswoman said. Friday afternoon, Steve Schwartz, a primary care doctor with a large practice in Montgomery County, Md., was struggling to use the vaccine he had: 95 Johnson & Johnson doses, set to expire on June 23, and Moderna doses that will be good until November. Schwartz, who once begged state officials for vaccine, hasn't ordered shots in two weeks. He keeps wait lists, has appealed to family and friends of staff, churches and synagogues and even the construction site next door. Most have gotten it; others are hesitant. "Suddenly the demand plummeted," he said. "We can't give it away." He recently spent 20 minutes gently debunking conspiracy theories parroted by a patient who mistrusts the media's reporting of the pandemic, believing the vaccine would make him sicker than the virus and that cases and deaths were overblown. "I have a dose for you and I can give to you today," Schwartz said he told him. But it was 3:30 in the afternoon and he didn't have an open vial, so Schwartz took a risk, asking the patient to return the next morning. He did. It doesn't always work out that way. Schwartz's practice has administered about 2,000 shots and wasted up to 20, he said. Although the numbers are small, Schwartz said they are devastating. "Knowing this could be helping someone and we're putting it in the garbage," he said, "it tears me up." The predicament is particularly acute for one of his colleagues, Rajshree Thaker, who has cousins, aunts and uncles in India, where new daily coronavirus cases exceeded 400,000. She video chats with a cousin on lockdown in India who almost couldn't get his second shot at a clinic giving 500 doses a day. At work in her Bethesda, Md., office, Thaker recently offered the vaccine to a patient who would have to drive five miles to the practice's Chevy Chase location where a vial was open. The patient couldn't be bothered. Thaker doesn't know if she ever got the shot. - - - The Washington Post's Lena H. Sun contributed to this report. Related ContentAt 95, Dick Van Dyke is still the consummate showman - and he's desperate to get back onstageThis Siberian town lost everything when the mill closed. It's now struggling to find a future.Everyone wants Garth Brooks on their side. He just wants everyone to get along.
The change is applicable to unopened vials, the European Medicines Agency (EMA) said, adding that the advice by its human medicines committee came after assessing additional stability study data submitted by Pfizer and BioNTech. "EMA is in continuous dialogue with the marketing authorisation holders of COVID-19 vaccines as they seek to make manufacturing improvements to enhance vaccine distribution in the EU," the watchdog said. U.S. authorities in February had approved storage and transport of the Pfizer-BioNTech vaccine at standard freezer temperatures of -15 to -25 degrees Celsius for up to two weeks instead of the ultra-cold temperatures between -80 to -60 degrees Celsius it usually requires.
The US will send at least 80 million doses of coronavirus vaccines abroad by the end of June; infections down in all 50 states. Latest COVID-19 news.
Thousands of new daily cases are overloading an already fragile health care system that lacks enough ventilators, oxygen and doctors to care for the sick.
In January 2020, Olympic shot putter Raven Saunders read a news article about Bryce Gowdy, a Black teenager from Deerfield Beach, Florida, who died by suicide.
A lab worker extracts DNA from samples for further tests at the AIDS Vaccine Design and Development Laboratory Dec. 1, 2008 in New York City. Chris Hondros/Getty ImagesSmallpox has been eradicated from the face of the Earth following a highly effective, worldwide vaccination campaign. Paralytic poliomyelitis is no longer a problem in the U.S. because of development and use of effective vaccines against the poliovirus. In current times, millions of lives have been saved because of rapid deployment of effective vaccines against COVID-19. And yet, it has been 37 years since HIV was discovered as the cause of AIDS, and there is no vaccine. Here I will describe the difficulties facing development of an effective vaccine against HIV/AIDS. I am a professor of pathology at the University of Miami Miller School of Medicine. My laboratory is credited with the discovery of the monkey virus called SIV, or simian immunodeficiency virus. SIV is the close monkey relative of the virus that causes AIDS in humans – HIV, or human immunodeficiency virus. My research has contributed importantly to the understanding of the mechanisms by which HIV causes disease and to vaccine development efforts. Dr. Anthony Fauci discusses the difficulty of finding a vaccine for HIV/AIDS in 2017. HIV vaccine development efforts have come up short Vaccines have unquestionably been society’s most potent weapon against viral diseases of medical importance. When the new disease AIDS burst onto the scene in the early 1980s and the virus that caused it was discovered in 1983-84, it was only natural to think that the research community would be able to develop a vaccine for it. At a now famous press conference in 1984 announcing HIV as the cause of AIDS, then U.S. Secretary of Health and Human Services Margaret Heckler predicted that a vaccine would be available in two years. Well, it is now 37 years later and there is no vaccine. The rapidity of COVID-19 vaccine development and distribution puts the lack of an HIV vaccine in stark contrast. The problem is not failure of government. The problem is not lack of spending. The difficulty lies in the HIV virus itself. In particular, this includes the remarkable HIV strain diversity and the immune evasion strategies of the virus. So far there have been five large-scale Phase 3 vaccine efficacy trials against HIV, each at a cost of over US$100 million. The first three of these failed quite convincingly; no protection against acquisition of HIV infection, no lowering of viral loads in those who did become infected. In fact, in the third of these trials, the STEP trial, there was a statistically significant higher frequency of infection in individuals who had been vaccinated. The fourth trial, the controversial Thai RV144 trial, initially reported a marginal degree of successful protection against the acquisition of HIV infection among vaccinated individuals. However, a subsequent statistical analysis reported that there was less than a 78% chance that the protection against acquisition was real. A fifth vaccine trial, the HVTN 702 trial, was ordered to confirm and extend the results of the RV144 trial. The HVTN702 trial was halted early because of futility. No protection against acquisition. No lowering of viral load. Ouch. The complexity of HIV What is the problem? The biological properties that HIV has evolved make development of a successful vaccine very, very difficult. What are those properties? First and foremost is the continuous unrelenting virus replication. Once HIV gets its foot in the door, it’s “gotcha.” Many vaccines do not protect absolutely against the acquisition of an infection, but they are able to severely limit the replication of the virus and any illness that might result. For a vaccine to be effective against HIV, it will likely need to provide an absolute sterilizing barrier and not just limit viral replication. HIV has evolved an ability to generate and to tolerate many mutations in its genetic information. The consequence of this is an enormous amount of variation among strains of the virus not only from one individual to another but even within a single individual. Let’s use influenza for a comparison. Everyone knows that people need to get revaccinated against influenza virus each season because of season-to-season variability in the influenza strain that is circulating. Well, the variability of HIV within a single infected individual exceeds the entire worldwide sequence variability in the influenza virus during an entire season. What are we going to put into a vaccine to cover this extent of strain variability? HIV has also evolved an incredible ability to shield itself from recognition by antibodies. Enveloped viruses such as coronaviruses and herpes viruses encode a structure on their surface that each virus uses to gain entry into a cell. This structure is called a “glycoprotein,” meaning that it is composed of both sugars and protein. But the HIV envelope glycoprotein is extreme. It is the most heavily sugared protein of all viruses in all 22 families. More than half the weight is sugar. And the virus has figured out a way, meaning the virus has evolved by natural selection, to use these sugars as shields to protect itself from recognition by antibodies that the infected host is trying to make. The host cell adds these sugars and then views them as self. These properties have important consequences relevant for vaccine development efforts. The antibodies that an HIV-infected person makes typically have only very weak neutralizing activity against the virus. Furthermore, these antibodies are very strain-specific; they will neutralize the strain with which the individual is infected but not the thousands and thousands of other strains circulating in the population. Researchers know how to elicit antibodies that will neutralize one strain, but not antibodies with an ability to protect against the thousands and thousands of strains circulating in the population. That’s a major problem for vaccine development efforts. HIV is continually evolving within a single infected individual to stay one step ahead of the immune responses. The host elicits a particular immune response that attacks the virus. This puts selective pressure on the virus, and through natural selection a mutated virus variant appears that is no longer recognized by the individual’s immune system. The result is continuous unrelenting viral replication. [Understand new developments in science, health and technology, each week. Subscribe to The Conversation’s science newsletter.] So, should we researchers give up? No, we shouldn’t. One approach researchers are trying in animal models in a couple of laboratories is to use herpes viruses as vectors to deliver the AIDS virus proteins. The herpes virus family is of the “persistent” category. Once infected with a herpes virus, you are infected for life. And immune responses persist not just as memory but in a continually active fashion. Success of this approach, however, will still depend on figuring out how to elicit the breadth of immune responses that will allow coverage against the vast complexity of HIV sequences circulating in the population. Another approach is to go after protective immunity from a different angle. Although the vast majority of HIV-infected individuals make antibodies with weak, strain-specific neutralizing activity, some rare individuals do make antibodies with potent neutralizing activity against a broad range of HIV isolates. These antibodies are rare and highly unusual, but we scientists do have them in our possession. Also, scientists have recently figured out a way to achieve protective levels of these antibodies for life from a single administration. For life! This delivery depends on a viral vector, a vector called adeno-associated virus. When the vector is administered to muscle, muscle cells become factories that continuously produce the potent broadly neutralizing antibodies. Researchers have recently documented continuous production for six and a half years in a monkey. **VL: I think it’s this paper, quote from abstract “Here we report that monkey 84-05 has successfully maintained 240–350 μg/ml of anti-SIV antibody 5L7 for over 6 years”: https://dx.doi.org/10.3389%2Ffimmu.2020.00449) We are making progress. We must not give up.This article is republished from The Conversation, a nonprofit news site dedicated to sharing ideas from academic experts. It was written by: Ronald C. Desrosiers, University of Miami. Read more:Should my child get the COVID-19 vaccine? 7 questions answered by a pediatric infectious disease expertHow HIV became a treatable, chronic disease Ronald C. Desrosiers receives funding from the National Institutes of Health.
The world's thirstiest beer drinkers finally clinked their pilsner mugs in the drizzle on Monday, as beer gardens opened despite unseasonably cold grey weather in the Czech Republic, a landmark event after five months of COVID-19 lockdown. "Finally I am sitting here as a human," said Martin Krisko, savouring his cold beer with a meal served hot, on a plate, rather than lukewarm in a plastic takeaway container, at the Beer Time pub in Prague's former industrial quarter Smichov. The Czech Republic, home to the original pilsner, consumes the most beer per capita in the world, and reopening its pubs for outdoor service is seen as an important step in its plans to relax its COVID-19 restrictions.
"People are nervous about this — I've heard it a zillion times," one expert tells Yahoo Life. "The mask has been their security blanket for 14-plus months."
The pressure on French hospitals from the coronavirus epidemic has eased further but two days before France reopens restaurants' outdoor terraces again, the slowdown in the number of new cases seen in the past two weeks came to a halt. The health ministry reported 3,350 new cases on Monday - when the case count usually drops due to the weekend - an increase of 1.74% compared to last Monday and the same week-on-week as on Sunday, when nearly 14,000 new cases were reported. The French government closely monitors week-on-week changes in the case tally, which feeds through to hospital and death tallies a few weeks later.
The Dutch port city of Rotterdam is preparing for a slimmed down version of the Eurovision song contest this weekend with a limited live audience, amid falling but still significant COVID-19 infection rates in the Netherlands. All 39 participating countries and their delegations are tested before they can enter the venue. This past weekend the organisers announced there had been infections found in members of the delegations from Poland and Iceland.
In a letter to the journal Science, top U.S. infectious disease experts join call for more information on the origins of the virus that causes COVID.
ROME (Reuters) -Italy's government on Monday approved a decree pushing back with immediate effect a nightly coronavirus curfew to 11 p.m. from 10 p.m. and easing other curbs in the regions where infections are low. Prime Minister Mario Draghi's government agreed the curfew would begin at midnight from June 7 and be abolished altogether from June 21 in those areas, a statement said, in line with a plan to gradually relax restrictions across the country. Italy, which has the second-highest COVID-19 death toll in Europe after Britain, has seen its daily deaths and cases decline in recent weeks, and more people are being vaccinated.
Dermatologists debunk myths like greasy food causes acne, pimples are only on your face, drinking water clears your skin, and aspirin stops breakouts.
The trailer for Prince Harry and Oprah Winfrey's mental health documentary series "The Me You Can't See" is here. "The Me You Can't See" was both co-created and executive produced by the Duke of Sussex and the talk show legend. The trailer gives viewers a look at the high-profile guests who join Harry and Winfrey to discuss emotional well-being, including Lady Gaga, Glenn Close and Zak Williams, son of the late Robin Williams, among others.
President Joe Biden said Monday that the U.S. will share an additional 20 million doses of COVID-19 vaccines with the world in the coming six weeks as domestic demand for shots drops and global disparities in distribution have grown more evident. The doses will come from existing production of Pfizer, Moderna or Johnson & Johnson vaccine stocks, marking the first time that U.S.-controlled doses of vaccines authorized for use in the country will be shared overseas. It will boost the global vaccine sharing commitment from the U.S. to 80 million.
The message "Vaccine saves, United for vaccines" was projected on Saturday onto the 98-foot (30-meter) statue by Unidos Pela Vacina (United by the Vaccine), in partnership with the Cristo Redentor Sanctuary and the Ogilvy Brazil advertising agency. In January, two healthcare workers received the first shots of coronavirus vaccines at the foot of the statue as Brazil kicked off its vaccination campaign.
Experts say the India variant probably will not cause great harm in the U.S. because of high vaccination rates, but they are watching it.
“We are a nation bobbing in multiple crises. Not one of them involves people taking COVID-19 too seriously.”
“The threat is increasingly concentrated among people who are vulnerable by choice.”
“This announcement would be very welcome if not for one big problem: There is no requirement for proof of vaccination.”
“Joining the protected vaccinated minority, which we hope will rapidly become the majority, is simple.”
“Instead of taking giant steps. I think we should be taking small steps toward the same goal.”